Abstract：
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma subtype, accounting for 15-20% of all lymphoma diagnoses. Although typically slow-growing and responsive to frontline therapies, advanced-stage FL remains incurable with current treatments and typically follows a chronic relapsing/remitting course with increasingly shorter responses to subsequent lines of therapy. Outcomes are highly variable; some patients experience prolonged first remissions that may approximate a \'functional cure\'. By contrast, a significant minority of patients experience disease progression shortly after frontline treatment resulting in high rates of lymphoma-related mortality. Reflecting on the heterogeneous natural history of FL, clinical practice varies widely, particularly in controversial areas, including appropriate disease staging, selection of management strategies and duration of clinical follow-up. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.
摘要：
滤泡性淋巴瘤（FL）是最常见的惰性非霍奇金淋巴瘤亚型，占所有淋巴瘤诊断的15-20%。虽然通常生长缓慢，对一线治疗有反应，晚期FL在目前的治疗中仍然无法治愈,通常遵循慢性复发/缓解过程,对后续治疗的反应越来越短.结果变化很大；一些患者经历了长时间的首次缓解，可能接近“功能性治愈”。相比之下,相当少的患者在一线治疗后不久出现疾病进展,导致淋巴瘤相关死亡率较高.反思FL的异质自然历史，临床实践差异很大，特别是在有争议的地区，包括适当的疾病分期，管理策略的选择和临床随访的持续时间。此立场陈述提供了基于证据的文献综合，以在澳大利亚实践中应用。
